Ocugen: Funding, Investors & Team (Sep 2026)
Ocugen is a biopharmaceutical company in the clinical stage that is dedicated to researching, developing, and selling gene therapies to treat eye diseases that can cause blindness. They are also working on developing a COVID-19 vaccine to help save lives. Their biologic product candidate is aimed at providing improved treatment options for patients with diseases like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, using a cutting-edge modifier gene therapy platform.
Ocugen has raised $258M across 6 funding rounds on record, the most recent an undisclosed round of $115M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ocugen Company Profile and Key Stats
Latest funding round on record: May 2026.
Ocugen Funding Rounds
Ocugen raised $53.5M in a Post-IPO Equity announced in Feb 2022.
1.3 years later, an undisclosed round of $16.5M was announced in May 2023.
1.5 years later, an undisclosed round of $30.0M was announced in Nov 2024.
9 months later, an undisclosed round of $20.0M was announced in Aug 2025.
5 months later, an undisclosed round of $22.5M was announced in Jan 2026.
4 months later, an undisclosed round of $115M was announced in May 2026.
Ocugen Founders and Leadership Team
Contact details for the Ocugen team: 1 of 2 have an email address on file.
Start 14-day free trial →Ocugen Funding Compared to Other Biotechnology Startups
Ocugen's latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ocugen in Biotechnology and Malvern
Companies Similar to Ocugen
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Ocugen Funding FAQs
What does Ocugen do?
Ocugen is a biopharmaceutical company in the clinical stage that is dedicated to researching, developing, and selling gene therapies to treat eye diseases that can cause blindness. They are also working on developing a COVID-19 vaccine to help save lives. Their biologic product candidate is aimed at providing improved treatment options for patients with diseases like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, using a cutting-edge modifier gene therapy platform.
How much funding has Ocugen raised?
Ocugen has raised $258M across 6 rounds on record. The most recent is an undisclosed round of $115M announced in May 2026.
When did Ocugen last raise funding?
Ocugen's most recent funding round on record is an undisclosed round of $115M, announced in May 2026.
Who founded Ocugen?
FundedIQ lists Uday B Kompella (Founder) at Ocugen.
Who is the CEO of Ocugen?
Shankar Musunuri is listed as CEO at Ocugen.
Where is Ocugen headquartered?
Ocugen is based in Malvern, Pennsylvania, United States.
How many employees does Ocugen have?
Ocugen is in the 101-250 employee band.
How does Ocugen's funding compare to other Biotechnology startups?
Ocugen's latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ocugen Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ocugen is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.